Anti-Orai1 antibody
AssigneeDaiichi Sankyo Company, Limited
InventorsTomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
Life of this patent
Estimating the term…
Abstract
It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
Claims19
An antibody or an antigen binding fragment of the antibody which specifically binds to the amino acid sequence represented by SEQ ID NO:
- 2, wherein the heavy chain sequence comprises a variable region having CDRH1, CDRH2, and CDRH3, and
- the light chain sequence comprises a variable region having CDRL1, CDRL2, and CDRL3 wherein the antibody or antigen binding fragment of the antibody is characterized by one of the following:
- (a) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO:
- 102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO:
- 106, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO:
- 110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO:
- 94, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO:
- 97, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO:
- 101;
- (b) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO:
- 102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO:
- 106, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO:
- 110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO:
- 95, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO:
- 98, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO:
- 101;
- (c) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO:
- 102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO:
- 107, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO:
- 110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO:
- 93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO:
- 96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO:
- 101;
- (d) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO:
- 102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO:
- 108, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO:
- 110, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO:
- 93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO:
- 96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO:
- 101;
- and
- (e) wherein the CDRH1 consists of the amino acid sequence represented by SEQ ID NO:
- 102, the CDRH2 consists of the amino acid sequence represented by SEQ ID NO:
- 104, the CDRH3 consists of the amino acid sequence represented by SEQ ID NO:
- 109, the CDRL1 consists of the amino acid sequence represented by SEQ ID NO:
- 93, the CDRL2 consists of the amino acid sequence represented by SEQ ID NO:
- 96, and the CDRL3 consists of the amino acid sequence represented by SEQ ID NO:
- 101.
Dependencies are inferred from the claim text.